Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study

BACKGROUND: Recent advances in adjuvant chemotherapy for early colon cancer have widened physicians' recommendations on the regimen and duration (3 or 6 months) of the treatment. We conducted this prospective study to evaluate whether the 12-gene recurrence score (12-RS) assay affected physicia...

Descripción completa

Detalles Bibliográficos
Autores principales: Oki, E., Watanabe, J., Sato, T., Kagawa, Y., Kuboki, Y., Ikeda, M., Ueno, H., Kato, T., Kusumoto, T., Masuishi, T., Yamaguchi, K., Kanazawa, A., Nishina, T., Uetake, H., Yamanaka, T., Yoshino, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134704/
https://www.ncbi.nlm.nih.gov/pubmed/33984677
http://dx.doi.org/10.1016/j.esmoop.2021.100146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134704/
https://www.ncbi.nlm.nih.gov/pubmed/33984677
http://dx.doi.org/10.1016/j.esmoop.2021.100146

Ejemplares similares